171 related articles for article (PubMed ID: 24531612)
1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.
García Del Muro X; Gallardo E; García Carbonero I; Laínez N; José Méndez M; Maroto P; Ochoa de Olza M; Puente J; Reynes G; Rubio J; Santander C; Suárez C; Vázquez Estévez S; Castellano D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1095-107. PubMed ID: 24531612
[TBL] [Abstract][Full Text] [Related]
2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
Calvo E; Maroto P; del Muro XG; Climent MA; González-Larriba JL; Esteban E; López R; Paz-Ares L; Bellmunt J; Castellano D
Cancer Metastasis Rev; 2010 Aug; 29 Suppl 1():1-10. PubMed ID: 20640589
[TBL] [Abstract][Full Text] [Related]
3. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
Kruck S; Bedke J; Kuczyk MA; Merseburger AS
Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
7. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
[TBL] [Abstract][Full Text] [Related]
8. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
9. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Calvo E; Ravaud A; Bellmunt J
Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
[TBL] [Abstract][Full Text] [Related]
10. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.
Porta C; Sabbatini R; Procopio G; Paglino C; Galligioni E; Ortega C
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1571-7. PubMed ID: 23181412
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
13. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
15. Current immunotherapeutic strategies in renal cell carcinoma.
Amato RJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
[TBL] [Abstract][Full Text] [Related]
16. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
17. Combination systemic therapy for advanced renal cell carcinoma.
Miller RE; Larkin JM
Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
[TBL] [Abstract][Full Text] [Related]
18. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Calvo E; Maroto P; del Muro XG; Climent MA; González-Larriba JL; Esteban E; López R; Paz-Ares L; Bellmunt J; Castellano D
Cancer Metastasis Rev; 2010 Aug; 29 Suppl 1():11-20. PubMed ID: 20640588
[TBL] [Abstract][Full Text] [Related]
19. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
20. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
